731 related articles for article (PubMed ID: 21801281)
1. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
2. Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer.
Han GZ; Liu ZJ; Shimoi K; Zhu BT
Cancer Res; 2005 Jan; 65(2):387-93. PubMed ID: 15695378
[TBL] [Abstract][Full Text] [Related]
3. Fulvestrant, a selective estrogen receptor down-regulator, sensitizes estrogen receptor negative breast tumors to chemotherapy.
Jiang D; Huang Y; Han N; Xu M; Xu L; Zhou L; Wang S; Fan W
Cancer Lett; 2014 May; 346(2):292-9. PubMed ID: 24462822
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
5. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
Sui M; Jiang D; Hinsch C; Fan W
Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
[TBL] [Abstract][Full Text] [Related]
6. Preclinical rationale for combined use of endocrine therapy and 5-fluorouracil but neither doxorubicin nor paclitaxel in the treatment of endocrine-responsive breast cancer.
Kurebayashi J; Nukatsuka M; Sonoo H; Uchida J; Kiniwa M
Cancer Chemother Pharmacol; 2010 Jan; 65(2):219-25. PubMed ID: 19455332
[TBL] [Abstract][Full Text] [Related]
7. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
[TBL] [Abstract][Full Text] [Related]
8. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.
Lu M; Miller KD; Gokmen-Polar Y; Jeng MH; Kinch MS
Cancer Res; 2003 Jun; 63(12):3425-9. PubMed ID: 12810680
[TBL] [Abstract][Full Text] [Related]
9. Oral fluoropyrimidine may augment the efficacy of aromatase inhibitor via the down-regulation of estrogen receptor in estrogen-responsive breast cancer xenografts.
Nukatsuka M; Saito H; Nakagawa F; Abe M; Uchida J; Shibata J; Matsuo K; Noguchi S; Kiniwa M
Breast Cancer Res Treat; 2011 Jul; 128(2):381-90. PubMed ID: 20809360
[TBL] [Abstract][Full Text] [Related]
10. Combination of standard cytotoxic agents with polyamine analogues in the treatment of breast cancer cell lines.
Hahm HA; Dunn VR; Butash KA; Deveraux WL; Woster PM; Casero RA; Davidson NE
Clin Cancer Res; 2001 Feb; 7(2):391-9. PubMed ID: 11234895
[TBL] [Abstract][Full Text] [Related]
11. The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.
Ikeda H; Taira N; Hara F; Fujita T; Yamamoto H; Soh J; Toyooka S; Nogami T; Shien T; Doihara H; Miyoshi S
Breast Cancer Res; 2010; 12(3):R43. PubMed ID: 20579400
[TBL] [Abstract][Full Text] [Related]
12. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo.
Chen Y; Alvarez EA; Azzam D; Wander SA; Guggisberg N; Jordà M; Ju Z; Hennessy BT; Slingerland JM
Breast Cancer Res Treat; 2011 Jul; 128(1):69-78. PubMed ID: 20669046
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
Chang J; Sui M; Fan W
Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
[TBL] [Abstract][Full Text] [Related]
14. Effects of CH4893237, a new orally active estrogen receptor downregulator, on breast cancer xenograft models with low serum estrogen levels.
Yoneya T; Tsunenari T; Taniguchi K; Kanbe Y; Morikawa K; Yamada-Okabe H; Lee YH; Lee MH; Kwon LS
Oncol Rep; 2009 Mar; 21(3):747-55. PubMed ID: 19212635
[TBL] [Abstract][Full Text] [Related]
15. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
[TBL] [Abstract][Full Text] [Related]
16. Effects of fulvestrant alone or combined with different steroids in human breast cancer cells in vitro.
Jansen GH; Franke HR; Wolbers F; Brinkhuis M; Vermes I
Climacteric; 2008 Aug; 11(4):315-21. PubMed ID: 18645697
[TBL] [Abstract][Full Text] [Related]
17. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
18. mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen.
Revillion F; Pawlowski V; Lhotellier V; Louchez MM; Peyrat JP
Anticancer Res; 2003; 23(2B):1455-60. PubMed ID: 12820409
[TBL] [Abstract][Full Text] [Related]
19. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
Andre F; Hatzis C; Anderson K; Sotiriou C; Mazouni C; Mejia J; Wang B; Hortobagyi GN; Symmans WF; Pusztai L
Clin Cancer Res; 2007 Apr; 13(7):2061-7. PubMed ID: 17404087
[TBL] [Abstract][Full Text] [Related]
20. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Pegram MD; Konecny GE; O'Callaghan C; Beryt M; Pietras R; Slamon DJ
J Natl Cancer Inst; 2004 May; 96(10):739-49. PubMed ID: 15150302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
